Arvinas (NASDAQ:ARVN) Announces Earnings Results, Beats Estimates By $2.95 EPS

Arvinas (NASDAQ:ARVN) issued its earnings results on Tuesday. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of ($0.37) by $2.95, FiscalAI reports. The business had revenue of $249.70 million for the quarter, compared to analysts’ expectations of $60.71 million. Arvinas had a return on equity of 2.01% and a net margin of 2.94%.The business’s revenue for the quarter was up 1014.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.84) EPS.

Here are the key takeaways from Arvinas’ conference call:

• VEPPANU was approved by the FDA as the first PROTAC degrader and licensed to Rigel, which is expected to make the drug available soon. The deal and approval generated substantial Q2 revenue, including a $50 million Pfizer milestone and $62.5 million in license revenue.
• Arvinas expects multiple clinical catalysts, including initial ARV-393 BCL-6 degrader data by year-end 2026, ARV-027 muscle-exposure and degradation data in the first half of 2027, and additional ARV-102 biomarker data in October.
• ARV-393 enrollment accelerated near predicted efficacious dose levels, but most 2026 data will come from earlier, likely subtherapeutic cohorts and include an unusually high proportion of T-cell lymphoma patients. More mature monotherapy and glofitamab-combination data, including DLBCL patients, are planned for 2027.
• Regulatory requests have pushed the start of ARV-102 trials in PSP from 2026 into 2027, delaying the program’s planned phase I-B and registrational-oriented studies.
• The company reported $567.9 million in cash, cash equivalents, and marketable securities and reiterated that its cash runway extends into the second half of 2028, supporting continued investment in its early-stage oncology and neurology pipeline.

Arvinas Stock Performance

NASDAQ ARVN traded up $0.26 during trading hours on Thursday, hitting $8.66. The company had a trading volume of 54,968 shares, compared to its average volume of 832,760. The business has a 50 day moving average of $8.06 and a 200-day moving average of $10.28. The company has a market cap of $558.49 million, a PE ratio of 86.51 and a beta of 1.71. Arvinas has a 1-year low of $6.05 and a 1-year high of $14.51.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Zacks Research upgraded Arvinas from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 26th. Wall Street Zen raised shares of Arvinas from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 26th. Wedbush lifted their price target on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research report on Wednesday. BTIG Research reiterated a “buy” rating and issued a $18.00 price objective on shares of Arvinas in a research report on Tuesday. Finally, Stephens restated an “overweight” rating and issued a $18.00 target price on shares of Arvinas in a research report on Wednesday, June 3rd. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Arvinas presently has an average rating of “Hold” and an average target price of $15.17.

Insider Transactions at Arvinas

In other news, CEO Randy Teel sold 9,657 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the sale, the chief executive officer owned 287,218 shares in the company, valued at approximately $2,854,946.92. This trade represents a 3.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 11,139 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $110,721.66. Following the sale, the chief financial officer directly owned 193,128 shares of the company’s stock, valued at $1,919,692.32. The trade was a 5.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 41,728 shares of company stock valued at $402,649 over the last three months. 7.30% of the stock is currently owned by insiders.

Institutional Trading of Arvinas

Several hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in shares of Arvinas in the first quarter valued at approximately $727,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Arvinas during the 1st quarter worth about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after purchasing an additional 2,122 shares during the period. Millennium Management LLC increased its position in Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after buying an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Arvinas by 108.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after acquiring an additional 469,394 shares during the period. 95.19% of the stock is currently owned by institutional investors.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.